Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus
- PMID: 17720721
- PMCID: PMC2735400
- DOI: 10.1136/ard.2007.076059
Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus
Abstract
Objective: To determine the features associated with acute onset systemic lupus erythaematosus (SLE).
Methods: A total of 631 SLE patients from LUMINA (for "lupus in minority populations: nature vs nurture"), a multiethnic (Hispanics, African-Americans and Caucasians) cohort, were studied. Acute disease onset was defined as the accrual of > or = 4 American College of Rheumatology (ACR) criteria for the classification of SLE in < or = 4 weeks. Socioeconomic demographic features, clinical manifestations, disease activity, damage accrual, mortality, autoantibodies, HLA class II and FCGR alleles, behavioural/psychological variables were compared between patients with acute and insidious disease onset by univariable (chi(2) and Student t test) and multivariable (stepwise logistic regression) analyses.
Results: A total of 94 (15%) patients had acute disease onset. In the multivariable analysis, patients with acute onset lupus had more renal involvement (odds ratio (OR) = 1.845, 95% CI 1.076-3.162; p = 0.026) and higher disease activity (OR = 1.057, 95% CI 1.005-1.112; p = 0.030). By contrast, age (OR = 0.976, 95% CI 0.956-0.997; p = 0.025), education (OR = 0.901, 95% CI 0.827-0.983, p = 0.019), health insurance (OR = 0.423, 95% CI 0.249-0.718; p = 0.001) and skin involvement (OR = 0.346, 95% CI 0.142-0.843; p = 0.019) were negatively associated with acute onset lupus. No differences were found regarding the serological, genetic and behavioural/psychological features; this was also the case for damage accrual and mortality.
Conclusions: Patients with acute onset lupus seem to be younger, have a lower socio-economic status and display more severe disease in terms of clinical manifestations and disease activity. However, intermediate (damage) and long-term (mortality) outcomes appear not to be influenced by the type of disease onset in SLE.
Similar articles
-
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.Arthritis Rheum. 2005 Jun;52(6):1655-64. doi: 10.1002/art.21048. Arthritis Rheum. 2005. PMID: 15934092
-
Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual.Arthritis Rheum. 2001 Dec;44(12):2797-806. doi: 10.1002/1529-0131(200112)44:12<2797::aid-art467>3.0.co;2-9. Arthritis Rheum. 2001. PMID: 11762940
-
Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group.Arthritis Rheum. 2001 Apr;45(2):191-202. doi: 10.1002/1529-0131(200104)45:2<191::AID-ANR173>3.0.CO;2-2. Arthritis Rheum. 2001. PMID: 11324784
-
What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?Autoimmun Rev. 2004 Jun;3(4):321-9. doi: 10.1016/j.autrev.2003.11.005. Autoimmun Rev. 2004. PMID: 15246029 Review.
-
Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort: The LUMINA (Lupus in Minorities: Nature vs. Nurture) Experience (LUMINA LXXXII).Rheum Dis Clin North Am. 2021 Feb;47(1):55-64. doi: 10.1016/j.rdc.2020.09.002. Epub 2020 Oct 29. Rheum Dis Clin North Am. 2021. PMID: 34042054 Review.
Cited by
-
P-glycoprotein and drug resistance in systemic autoimmune diseases.Int J Mol Sci. 2014 Mar 20;15(3):4965-76. doi: 10.3390/ijms15034965. Int J Mol Sci. 2014. PMID: 24658440 Free PMC article. Review.
-
Disparities in lupus care and outcomes.Curr Opin Rheumatol. 2009 Mar;21(2):102-9. doi: 10.1097/BOR.0b013e328323daad. Curr Opin Rheumatol. 2009. PMID: 19339919 Free PMC article. Review.
-
Delays to Care in Pediatric Lupus Patients: Data From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.Arthritis Care Res (Hoboken). 2018 Mar;70(3):420-427. doi: 10.1002/acr.23285. Epub 2018 Feb 7. Arthritis Care Res (Hoboken). 2018. PMID: 28544820 Free PMC article.
-
Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.Biomed Res Int. 2014;2014:704207. doi: 10.1155/2014/704207. Epub 2014 Aug 17. Biomed Res Int. 2014. PMID: 25243173 Free PMC article.
References
-
- Becker-Merok A, Nossent HC. Damage accumulation systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006;33:1570–1577. - PubMed
-
- Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–2557. - PubMed
-
- Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3:423–453. - PubMed
-
- Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AD, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”. Autoimmun Rev. 2006;5:180–186. - PubMed
-
- Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997;24:1061–1065. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials